Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon
Rbab Taha,1 Hadeel El-Haddad,1 Abdulqader Almuallim,2 Fatma Alshaiki,3 Elaf Obaid,2 Hani Almoallim1,2,4 1Department of Medicine, Dr Soliman Fakeeh Hospital, Jeddah, 2Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Mecca, 3Department of Medicine, East Jeddah Hospital, Jeddah, 4Rh...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/685aeb1ae88243408a013edf0fa86feb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:685aeb1ae88243408a013edf0fa86feb |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:685aeb1ae88243408a013edf0fa86feb2021-12-02T01:11:38ZSystematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon1179-156Xhttps://doaj.org/article/685aeb1ae88243408a013edf0fa86feb2017-12-01T00:00:00Zhttps://www.dovepress.com/systematic-review-of-the-role-of-rituximab-in-treatment-of-antineutrop-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XRbab Taha,1 Hadeel El-Haddad,1 Abdulqader Almuallim,2 Fatma Alshaiki,3 Elaf Obaid,2 Hani Almoallim1,2,4 1Department of Medicine, Dr Soliman Fakeeh Hospital, Jeddah, 2Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Mecca, 3Department of Medicine, East Jeddah Hospital, Jeddah, 4Rheumatic Diseases, Umm Al-Qura University, Mecca, Saudi Arabia Abstract: Rituximab (RTX) is established for the treatment of rheumatoid arthritis. This systematic review of the literature since 2006 summarizes evidence for the use of RTX in the treatment of additional rheumatological diseases: antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV), hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Data from randomized controlled trials are available only for AAV, confirming efficacy for remission induction, including in disease resistant to conventional treatment, and maintenance of remission. Further studies are required to confirm optimal maintenance regimens in AAV, important questions needing to be addressed including protocol administration versus treatment in response to clinical relapse and the importance of maintaining B-cell depletion. Sufficient data are available in other diseases to suggest RTX to be useful and that randomized controlled trials should be conducted. Keywords: anti-CD20 monoclonal antibody, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, refractory ankylosing spondylitis, resistant cryoglobulinemic vasculitis, refractory rheumatological diseases Taha REl-Haddad HAlmuallim AAlshaiki FObaid EAlmoallim HDove Medical PressarticleRituximabANCA-associated vasculitishepatitis C virus related cryoglobulinemic vasculitisHenoch-Schönlein purpuraankylosing spondylitisRaynaud’s phenomenonDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 9, Pp 201-214 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Rituximab ANCA-associated vasculitis hepatitis C virus related cryoglobulinemic vasculitis Henoch-Schönlein purpura ankylosing spondylitis Raynaud’s phenomenon Diseases of the musculoskeletal system RC925-935 |
| spellingShingle |
Rituximab ANCA-associated vasculitis hepatitis C virus related cryoglobulinemic vasculitis Henoch-Schönlein purpura ankylosing spondylitis Raynaud’s phenomenon Diseases of the musculoskeletal system RC925-935 Taha R El-Haddad H Almuallim A Alshaiki F Obaid E Almoallim H Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| description |
Rbab Taha,1 Hadeel El-Haddad,1 Abdulqader Almuallim,2 Fatma Alshaiki,3 Elaf Obaid,2 Hani Almoallim1,2,4 1Department of Medicine, Dr Soliman Fakeeh Hospital, Jeddah, 2Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Mecca, 3Department of Medicine, East Jeddah Hospital, Jeddah, 4Rheumatic Diseases, Umm Al-Qura University, Mecca, Saudi Arabia Abstract: Rituximab (RTX) is established for the treatment of rheumatoid arthritis. This systematic review of the literature since 2006 summarizes evidence for the use of RTX in the treatment of additional rheumatological diseases: antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV), hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Data from randomized controlled trials are available only for AAV, confirming efficacy for remission induction, including in disease resistant to conventional treatment, and maintenance of remission. Further studies are required to confirm optimal maintenance regimens in AAV, important questions needing to be addressed including protocol administration versus treatment in response to clinical relapse and the importance of maintaining B-cell depletion. Sufficient data are available in other diseases to suggest RTX to be useful and that randomized controlled trials should be conducted. Keywords: anti-CD20 monoclonal antibody, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, refractory ankylosing spondylitis, resistant cryoglobulinemic vasculitis, refractory rheumatological diseases |
| format |
article |
| author |
Taha R El-Haddad H Almuallim A Alshaiki F Obaid E Almoallim H |
| author_facet |
Taha R El-Haddad H Almuallim A Alshaiki F Obaid E Almoallim H |
| author_sort |
Taha R |
| title |
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| title_short |
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| title_full |
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| title_fullStr |
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| title_full_unstemmed |
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon |
| title_sort |
systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis c virus-related cryoglobulinemic vasculitis, henoch–schönlein purpura, ankylosing spondylitis, and raynaud's phenomenon |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/685aeb1ae88243408a013edf0fa86feb |
| work_keys_str_mv |
AT tahar systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon AT elhaddadh systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon AT almuallima systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon AT alshaikif systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon AT obaide systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon AT almoallimh systematicreviewoftheroleofrituximabintreatmentofantineutrophilcytoplasmicautoantibodyassociatedvasculitishepatitiscvirusrelatedcryoglobulinemicvasculitishenochndashschoumlnleinpurpuraankylosingspondylitisandraynaud39sphenomenon |
| _version_ |
1718403260160671744 |